Michael Harder


PhD Student


HCI G-322


+41-44-633 4171


Michael Harder



Study of Biomedical Chemistry at Johannes-Gutenberg-University Mainz.


Research Exchange with Prof. G. M. Whitesides at Harvard University.


Diploma Thesis with Prof. A. Hoffmann-Roeder at University of Mainz and Prof. G. M. Whitesides at Harvard University.

since 2010:

Graduate Student with Prof. F. Diederich, ETH Zurich.


Structure Based Design and Synthesis of Novel Inhibitors of the Kinase IspE

Malaria is assumed to cause 300 to 500 million infections per year. Moreover, about one-third of the world population is infected with Mycobacterium tuberculosis. The emergence of multi-drug resistant strains of Plasmodium falciparum and Mycobacterium tuberculosis reveals the necessity of new drugs with novel modes of action. The non-mevalonate-pathway is used exclusively by many pathogens but not by humans for the biosynthesis of isoprenoids. This fact makes the enzymes of the non-mevalonate-pathways promising targets for the development of new drugs against Malaria and Tuberculosis.
The aim of this project is the de novo design and synthesis of inhibitors against 4-diphosphocytidyl-2C-methyl-D-erythritol kinase (CDP-ME kinase, IspE). The design will be done with MOLOC, a molecular modeling programm developed by Hoffmann-La Roche. Biological evaluation of the inhibitors and X-ray crystallography of protein-ligand complexes will be used to study and optimize promising inhibitors.

Last update: July 2010